Recent Finacing
Recent Raise
Beijing Mabworks Biotech is a gene-engineering monoclonal-antibody company developing therapeutic antibodies and biosimilars, including ZMapp Ebola treatment and clinical-stage candidates MIL60 (Avastin biosimilar) and MIL62 (CLL).
Focus Areas
Recent Investors
Total Raised
Funding round
Investor